Journal of Neurodegeneration and Regeneration Home Page

Until now, no journal has put the whole spectrum of neurodegeneration and regeneration from basic clinical research to case studies between its covers. With the introduction of the Journal of Neurodegeneration and Regeneration that now happens as the nation's top experts in the field bring to the medical community a long awaited exploration of the basic and clinical new and ongoing research being conducted in this critical field, research that will lead to better diagnosis, more effective treatments and ultimately, perhaps, cures.

Although great progress has been made in recent years toward understanding neurodegenerative diseases like Alzheimer's, Parkinson's, multiple sclerosis, ALS and others, few effective treatments and no cures are currently available. So the element of urgency is here. The numbers speak for themselves. In the United States alone, over four million suffer from Alzheimer's disease; one million from Parkinson's disease; 350,000 from multiple sclerosis; and 20,000 from ALS. Worldwide, these four diseases account for more than 20 million patients.

Further, it is generally accepted that things are going to get worse before they get better. Aging greatly increases the risk of neurodegenerative disease and the average age of Americans and the populations of many other countries is increasing. Today, over 35 million Americans alone are over the age of 65. Within the next 30 years this number is likely to double, putting more and more people at increased risk of neurodegenerative diseases.

The Journal of Neurodegeneration and Regeneration will be guided by an editorial review board of the country's foremost experts in the field under the leadership of Gregory T. Carter, MD, Clinical Professor of Rehabilitation Medicine, University of Washington, School of Medicine, Seattle, Washington; Adjunct Professor of Physical Medicine and Rehabilitation, University of California Davis, School of Medicine, Davis, California, and Co-editors in Chief Michael David Weiss, MD, Adjunct Assistant Professor, Department of Rehabilitation Medicine, Assistant Professor, Director, EMG Laboratory, Co-Director MDA/ALS Center, Department of Neurology, University of Washington Medical Center, Seattle, Washington; Ali Samii, MD, Associate Professor of Neurology, University of Washington, Seattle, Washington; Lisa Stroud Krivickas, MD, Associate Professor, Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, Massachusetts; and Patrick Weydt, MD, Department of Neurology, University of Ulm, Ulm, Germany.

Its primary focus will be on recent developments in understanding the molecular mechanisms of neurodegenreration, neuroprotection and neuroregeneration including experimental approaches and their relevance in treating neurodegenerative disorders. Readers now have access to in-depth coverage of such things as:

Recent developments in understanding the molecular mechanisms of neurodegeneration and neuroprotection
The role of acetylcholinesterase in neurodegenerative diseases
Understanding the aetiology of major neurodegenerative diseases and identifying ways of early detection
The pathophysiological function of JNK
The role of extracellular proteolysis by metalloproteases such as ADAMB in neuroprotection

Subscription information	Advertising information	Current table of contents	Editorial board	Abstracts
Order reprints			Manuscript submission